製品番号: HY-100434

PD-161570

カスタマーレビュー

Based on 1 Customer Validation

PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC₅₀ of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC₅₀ values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC₅₀s of 450 nM and 622 nM, respectively. PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.82%
CAS 番号: 192705-80-9
分子式: C₂₆H₃₅Cl₂N₇O
分子量:532.51

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

PD-161570 構造式

CAS 番号: 192705-80-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC₅₀ of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC₅₀ values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC₅₀s of 450 nM and 622 nM, respectively^[1]^[2]. PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor^[3].

IC₅₀ & Target^[1]^[2]^[3]

FGFR1

39.9 nM (IC₅₀)

FGFR1

42 nM (Ki)

FGFR1 autophosphorylation

622 nM (IC₅₀)

PDGFRβ

262 nM (IC₅₀)

PDGFR

310 nM (IC₅₀)

EGFR

240 nM (IC₅₀)

c-Src

44 nM (IC₅₀)

TGF-β Receptor

PDGFR アイソフォーム固有の製品をすべて表示 :

EGFR アイソフォーム固有の製品をすべて表示 :

Src アイソフォーム固有の製品をすべて表示 :

TGF-β Receptor アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
C6	IC₅₀	5.8 μM Compound: 33	Inhibition of C-6 rat glioma cell proliferation Inhibition of C-6 rat glioma cell proliferation	[PMID: 11384237]
HCT-8	IC₅₀	16.3 μM Compound: 33	Inhibition of human colon carcinoma HCT-8 cell proliferation Inhibition of human colon carcinoma HCT-8 cell proliferation	[PMID: 11384237]
HT-29	IC₅₀	0.9 μM Compound: 33	Inhibition of human colon carcinoma HT-29 cell proliferation Inhibition of human colon carcinoma HT-29 cell proliferation	[PMID: 11384237]
SW-620	IC₅₀	>25 μM Compound: 33	Inhibition of human colon carcinoma SW-620 cell proliferation Inhibition of human colon carcinoma SW-620 cell proliferation	[PMID: 11384237]

体外実験

PD-161570 (Compound 6c; 0.1-1 μM; 1-8 days; VSMCs) treatment inhibits PDGF-stimulated vascular smooth muscle cell proliferation in a dose dependent fashion with an IC₅₀ of 0.3 μM on day 8^[1].
PD-161570 suppresses constitutive phosphorylation of the FGF-1 receptor in both human ovarian carcinoma cells (A_121(p)) and Sf9 insect cells overexpressing the human FGF-1 receptor and blocked the growth of A_121(p) cells in culture^[2].
PD-161570 can potently inhibit basic fibroblast growth factor (bFGF)-mediated angiogenesis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Vascular smooth muscles cells (VSMCs)
Concentration:

0.1 µM, 0.3 µM, 1 µM
Incubation Time:

1 day, 3 days, 6 days, 8 days
Result:

Inhibited VSMC proliferation in a dose dependent fashion with an IC₅₀ of 0.3 µM at day 8.

化学情報

CAS 番号 192705-80-9
性状 Solid
分子量 532.51
分子式 C₂₆H₃₅Cl₂N₇O
Color Light yellow to yellow
SMILES

O=C(NC(C)(C)C)NC1=NC2=NC(NCCCCN(CC)CC)=NC=C2C=C1C3=C(Cl)C=CC=C3Cl
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 33.33 mg/mL (62.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8779 mL

9.3895 mL

18.7790 mL

5 mM

0.3756 mL

1.8779 mL

3.7558 mL

10 mM

0.1878 mL

0.9389 mL

1.8779 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (275 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Hamby JM, et al. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem. 1997 Jul 18;40(15):2296-303. [Content Brief]

[2]. Batley BL, et al. Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 1998;62(2):143-50. [Content Brief]

[3]. Kyosuke Hino, et al. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva. Stem Cell Reports. 2018 Nov 13;11(5):1106-1119. [Content Brief]

[4]. Wolfe A, et al. Pharmacologic characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds. J Biomol Screen. 2013 Dec;18(10):1234-45. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8779 mL	9.3895 mL	18.7790 mL	46.9475 mL
	5 mM	0.3756 mL	1.8779 mL	3.7558 mL	9.3895 mL
	10 mM	0.1878 mL	0.9389 mL	1.8779 mL	4.6947 mL
	15 mM	0.1252 mL	0.6260 mL	1.2519 mL	3.1298 mL
	20 mM	0.0939 mL	0.4695 mL	0.9389 mL	2.3474 mL
	25 mM	0.0751 mL	0.3756 mL	0.7512 mL	1.8779 mL
	30 mM	0.0626 mL	0.3130 mL	0.6260 mL	1.5649 mL
	40 mM	0.0469 mL	0.2347 mL	0.4695 mL	1.1737 mL
	50 mM	0.0376 mL	0.1878 mL	0.3756 mL	0.9389 mL
	60 mM	0.0313 mL	0.1565 mL	0.3130 mL	0.7825 mL

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

PD-161570

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

TGF-beta/Smad Compound Library

Anti-Cancer Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

RNA Binding Bioactive Compound Library

PDGFR アイソフォーム固有の製品をすべて表示

EGFR アイソフォーム固有の製品をすべて表示

Src アイソフォーム固有の製品をすべて表示

TGF-β Receptor アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

PD-161570 関連分類

HY-100434 関連分類